Stockscreener 앱 받기
8.76
0.69%
0.06
전일 마감가:
$8.70
열려 있는:
$8.67
하루 거래량:
4.58M
Relative Volume:
0.74
시가총액:
$2.28B
수익:
$6.28B
순이익/손실:
$700.00M
주가수익비율:
3.2538
EPS:
2.6922
순현금흐름:
$537.00M
1주 성능:
+8.82%
1개월 성능:
+25.68%
6개월 성능:
-9.03%
1년 성능:
-45.86%
1일 변동 폭
$8.61
$8.80
1주일 범위
$7.96
$8.80
52주 변동 폭
$6.18
$17.23
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
8.76 | 2.26B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon (OGN) Receives FDA Approval for Nexplanon Label Expansion to 5 Years - Intellectia AI
Organon wins FDA nod to expand use of Nexplanon birth control implant - Seeking Alpha
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Exte - PharmiWeb.com
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - The AI Journal
Birth control implant Nexplanon now approved to last 5 years in US - Stock Titan
About Us - FinancialContent
Organon (OGN) Receives FDA Approval to Extend NEXPLANON Use to 5 Years - Intellectia AI
Organon (OGN) Receives FDA Approval for NEXPLANON Extended Use Up to 5 Years - Intellectia AI
Performance Recap: Whats the beta of Organon Co stockJuly 2025 Earnings & Detailed Earnings Play Alerts - baoquankhu1.vn
Global Organon employees on leading Pride Network and building inclusive workplaces - attitude.co.uk
Earnings Recap: Whats the beta of Organon Co stockLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Organon (OGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Organon and Co put volume heavy and directionally bearish - TipRanks
Nordea Investment Management AB Has $31.71 Million Position in Organon & Co. $OGN - MarketBeat
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know - sharewise.com
Validea Kenneth Fisher Strategy Daily Upgrade Report2/14/2025 - Intellectia AI
Organon & Co. (OGN) Stock Analysis: Exploring a 15% Potential Upside Amidst Diverse Product Portfolio - DirectorsTalk Interviews
Aug Levels: Will Organon Co stock see PE expansionEarnings Recap Report & High Yield Equity Trading Tips - Bộ Nội Vụ
Organon Shares Show Signs of a Turnaround - AD HOC NEWS
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Short Squeeze: How Organon Co stock reacts to inflationary pressuresCPI Data & Precise Buy Zone Tips - moha.gov.vn
Organon & Co. (NYSE:OGN) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Organon & Co. $OGN Shares Sold by Philip James Wealth Mangement LLC - MarketBeat
Why Organon (OGN) Is Up 13.4% After Expanding Nilemdo Rights In Six European Markets - Yahoo Finance
Assessing Organon (OGN) Valuation After Short Term Share Price Momentum And Long Term Weak Returns - Yahoo Finance
Organon poised to extend rally to seventh consecutive session - MSN
Assessing Organon (OGN) Valuation After New Nilemdo Cholesterol Therapy Agreement - simplywall.st
Organon, Daiichi Sankyo Europe enter commercialization pact for Nilemdo - TipRanks
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo®? in France, Denmark, Iceland, Sweden, Finland and Norway - marketscreener.com
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo - Business Wire
Organon Named Top Dividend Stock With Insider Buying and 0.99% Yield (OGN) - Nasdaq
Organon & Co. (OGN) Stock Analysis: Exploring The 25.77% Potential Upside For Investors - DirectorsTalk Interviews
Is Organon (NYSE:OGN) A Risky Investment? - 富途牛牛
Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN) - MarketBeat
Great week for Organon & Co. (NYSE:OGN) institutional investors after losing 51% over the previous year - simplywall.st
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Samsung Bioepis Denies Organon Deal Rumors - Citeline News & Insights
Samsung Bioepis pursues direct sales by weighing Organon acquisition to boost profitsCHOSUNBIZ - Chosunbiz
Samsung Bioepis reviews Organon acquisition to boost direct biosimilar salesCHOSUNBIZ - Chosunbiz
Mixed Martial Arts Group Limited Stock Analysis and ForecastTechnical Resistance Breaks & Stay One Step Ahead of Risk Events - earlytimes.in
Organon & Co. (NYSE:OGN) Upgraded at Wall Street Zen - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Understanding the Setup: (OGN) and Scalable Risk - Stock Traders Daily
Will Organon Co 7XP stock outperform value peersMarket Growth Report & Fast Exit and Entry Trade Guides - moha.gov.vn
Volume Summary: How Organon Co stock reacts to inflationary pressuresBreakout Watch & Expert-Curated Trade Recommendations - moha.gov.vn
Organon & Co. (OGN) Stock Analysis: A Closer Look at Its 31.61% Potential Upside and What It Means for Investors - DirectorsTalk Interviews
Does Organon’s 50% Share Price Slide Signal Opportunity in 2025? - Yahoo Finance
Gilman Hill Asset Management LLC Reduces Position in Organon & Co. $OGN - MarketBeat
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com
Why (OGN) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.85%
3.01%
자본화:
|
볼륨(24시간):